Yahoo
Amezalpat (TPST-1120) is Phase 3-ready: completed FDA and EMA interactions for first-line pivotal study in hepatocellular carcinoma (HCC); global investigator support in placeAwarded both Orphan Drug & Fast Track designations for amezalpat based on positive randomized Phase 2 data in first-line HCC Received FDA “Study May Proceed” letter for TPST-1495 in a Phase 2 trial for the treatment of familial adenomatous polyposis (FAP); data expected 2026 BRISBANE, Calif., April 09, 2025 (GLOBE NEWSWIRE)
Yahoo
• Granted Both Orphan Drug & Fast Track designations for Amezalpat (TPST-1120) for the treatment of patients with Hepatocellular Carcinoma (HCC)• Announced Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line HCC Pivotal Trial• Received FDA “Study May Proceed” letter for Phase 2 trial of TPST-1495 for the treatment of Familial Adenomatous Polyposis (FAP) BRISBANE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clini
Yahoo
Clinical data supporting mechanism of action reinforce potential as a novel cancer treatmentBRISBANE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that an abstract highlighting data supporting the immune component of amezalpat’s purported mechanism of action has been accepted for poster presentation at the 2025 Ameri
Yahoo
Second clinical program entering Phase 2 with data expected 2026BRISBANE, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the Cancer Prevention Clinical Trials Network received a “Study May Proceed” letter from the U.S. Food and Drug Administration (FDA) to evaluate TPST-1495, the company’s novel dual receptor inhi
Yahoo
Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC Amezalpat builds momentum with both Fast Track and Orphan Drug Designations BRISBANE, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FT
Yahoo
BRISBANE, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted one employee nonqualified stock options to purchase an aggregate of 45,000 shares of its common stock under the Company’s 2023 Inducement Plan. The stock options will vest over a four-year
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
UUU | 0.06% | $4.93M | +40.20% | 0.00% |
NAT | -0.11% | $575.96M | -36.00% | 12.41% |
LMT | -0.17% | $108.98B | +0.07% | 2.79% |
HMY | -0.25% | $9.01B | +54.87% | 1.23% |
MOH | -0.27% | $17.02B | -8.99% | 0.00% |
GFI | -0.30% | $18.61B | +31.67% | 2.75% |
DG | -0.32% | $20.45B | -36.56% | 2.55% |
PPC | 0.37% | $11.21B | +41.54% | 0.00% |
IAG | 0.42% | $3.60B | +42.27% | 0.00% |
FMTO | -0.43% | $45.74M | -99.96% | 0.00% |
MVO | -0.47% | $66.70M | -38.82% | 21.64% |
PRA | -0.51% | $1.19B | +58.17% | 0.00% |
QNTM | 0.54% | $21.04M | -55.31% | 0.00% |
T | -0.58% | $196.66B | +57.98% | 4.07% |
AMT | -0.59% | $99.10B | +8.59% | 3.09% |
AU | -0.76% | $20.37B | +64.23% | 2.29% |
COR | 0.88% | $55.43B | +28.90% | 0.56% |
CYCN | 0.91% | $9.37M | +2.39% | 0.00% |
KNOP | 0.94% | $226.71M | +23.32% | 1.57% |
VSA | 1.10% | $7.04M | -49.24% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
SRG | 41.95% | $165.03M | -52.82% | 0.00% |
ATR | 41.27% | $10.23B | +5.02% | 1.16% |
NCZ | 41.26% | - | - | 5.92% |
RWAY | 41.09% | $372.35M | -14.36% | 11.27% |
SLAB | 40.88% | $4.34B | +2.29% | 0.00% |
DCI | 40.86% | $8.37B | -5.24% | 1.54% |
VREX | 40.03% | $327.44M | -48.23% | 0.00% |
RITM | 39.98% | $6.17B | +1.48% | 8.61% |
CRSR | 39.75% | $903.71M | -23.68% | 0.00% |
BCO | 39.65% | $3.72B | -9.19% | 0.82% |
POWI | 39.61% | $3.05B | -30.13% | 1.49% |
NEWT | 39.00% | $295.56M | -19.97% | 6.77% |
AVNT | 38.61% | $3.48B | -16.80% | 2.78% |
RXRX | 38.59% | $1.73B | -55.31% | 0.00% |
SYNA | 38.59% | $2.52B | -29.56% | 0.00% |
GCI | 38.55% | $518.38M | -0.28% | 0.00% |
AER | 38.50% | $20.06B | +25.28% | 1.14% |
QCOM | 38.35% | $167.57B | -21.04% | 2.23% |
KN | 38.34% | $1.48B | -2.96% | 0.00% |
IR | 38.17% | $33.49B | -9.19% | 0.12% |
Current Value
$6.321 Year Return
Current Value
$6.321 Year Return
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
TAIL | -41.29% | $140.49M | 0.59% |
VIXY | -39.99% | $109.64M | 0.85% |
BTAL | -27.95% | $361.41M | 1.43% |
XONE | -26.81% | $603.24M | 0.03% |
IVOL | -23.33% | $353.94M | 1.02% |
BILS | -20.80% | $3.96B | 0.1356% |
SPTS | -20.26% | $5.76B | 0.03% |
XHLF | -18.73% | $1.46B | 0.03% |
VGSH | -18.66% | $22.38B | 0.03% |
UTWO | -18.06% | $387.71M | 0.15% |
ULST | -17.67% | $637.77M | 0.2% |
XBIL | -17.03% | $782.40M | 0.15% |
IBTG | -16.99% | $1.88B | 0.07% |
IBTH | -16.77% | $1.53B | 0.07% |
FXY | -16.74% | $838.61M | 0.4% |
FTSD | -16.70% | $212.46M | 0.25% |
SCHO | -15.80% | $10.87B | 0.03% |
GBIL | -15.65% | $6.17B | 0.12% |
SHY | -15.12% | $24.03B | 0.15% |
IBTI | -14.29% | $995.39M | 0.07% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
QQQJ | 45.52% | $610.08M | 0.15% |
XT | 45.35% | $3.24B | 0.46% |
RYLD | 44.95% | $1.29B | 0.6% |
YYY | 44.90% | $538.81M | 3.25% |
KJUL | 44.82% | $113.35M | 0.79% |
GNOM | 44.40% | $40.65M | 0.5% |
IBUY | 44.02% | $153.59M | 0.65% |
PCEF | 43.98% | $788.02M | 3.07% |
IWM | 43.92% | $63.95B | 0.19% |
ISCG | 43.89% | $645.00M | 0.06% |
IWO | 43.87% | $11.36B | 0.24% |
QCLN | 43.83% | $417.91M | 0.59% |
VTWO | 43.82% | $12.07B | 0.07% |
IWC | 43.82% | $766.88M | 0.6% |
BALT | 43.78% | $1.44B | 0.69% |
FV | 43.75% | $3.60B | 0.87% |
RSPA | 43.71% | $319.03M | 0.29% |
SMMD | 43.68% | $1.46B | 0.15% |
VBK | 43.66% | $18.33B | 0.07% |
SCHA | 43.63% | $16.91B | 0.04% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
KCCA | -0.07% | $97.18M | 0.87% |
BSCP | -0.13% | $3.49B | 0.1% |
FLMI | -0.13% | $649.76M | 0.3% |
GSY | -0.21% | $2.79B | 0.22% |
UNG | 0.24% | $371.83M | 1.06% |
JBND | -0.31% | $1.92B | 0.25% |
MMIN | 0.33% | $469.53M | 0.3% |
FXC | -0.38% | $87.40M | 0.4% |
IBMS | 0.39% | $69.47M | 0.18% |
YEAR | 0.44% | $1.40B | 0.25% |
TPMN | -0.45% | $31.54M | 0.65% |
GNMA | -0.50% | $355.60M | 0.1% |
OWNS | 0.51% | $134.57M | 0.3% |
NYF | 0.52% | $875.13M | 0.25% |
CGCB | 0.52% | $2.19B | 0.27% |
ISTB | -0.54% | $4.45B | 0.06% |
TOTL | -0.61% | $3.59B | 0.55% |
SMMU | 0.72% | $822.53M | 0.35% |
BSSX | 0.73% | $75.11M | 0.18% |
JMBS | -0.76% | $5.40B | 0.22% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CBOE | -13.47% | $22.95B | +20.67% | 1.12% |
HUSA | -9.11% | $9.73M | -55.71% | 0.00% |
CME | -6.87% | $98.74B | +28.80% | 3.84% |
TU | -5.93% | $23.77B | -4.62% | 7.19% |
CREG | -5.78% | $16.80M | -32.73% | 0.00% |
SEG | -5.24% | $239.93M | -26.61% | 0.00% |
PULM | -5.17% | $23.82M | +239.64% | 0.00% |
NOC | -5.08% | $67.51B | -0.35% | 1.76% |
DOGZ | -4.90% | $231.95M | +120.05% | 0.00% |
MO | -4.03% | $97.80B | +26.35% | 6.94% |
PHYS.U | -3.68% | - | - | 0.00% |
MKTX | -2.70% | $8.01B | -1.42% | 1.39% |
PSQH | -2.66% | $89.26M | -49.87% | 0.00% |
VRCA | -2.41% | $59.36M | -92.99% | 0.00% |
DRD | -1.88% | $1.23B | +63.69% | 2.01% |
ED | -1.83% | $36.75B | +5.26% | 3.28% |
CNC | -1.70% | $29.89B | -22.14% | 0.00% |
VHC | -1.69% | $34.69M | +74.89% | 0.00% |
K | -1.61% | $28.49B | +32.17% | 2.77% |
LTM | -1.27% | $11.01B | -96.75% | 2.75% |